Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Morvarid Rezaie

Hospice and Palliative Medicine Fort Worth, TX Doctor of Osteopathy

NPI 1164692026 CMS profile 710232

800 W Magnolia Ave, Fort Worth, TX 76104

Open in the dashboard

General payments

$3,513

173 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Morvarid Rezaie of Fort Worth, TX is reported in the CMS Open Payments database as having received $3,513 across 173 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Hospice and Palliative Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,053 41
2024 General $424 19
2023 General $368 12
2022 General $401 26
2021 General $556 37
2020 General $478 24
2019 General $233 14

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Morvarid Rezaie
  • Hospice and Palliative Medicine median
  • Middle half of Hospice and Palliative Medicine
  • National median

In program year 2025, general payments to Morvarid Rezaie were reported at $1,053. Among 378 Hospice and Palliative Medicine profiles paid that year, the median was $78 and the middle half received between $28 and $160.

Show as a table
Year Morvarid Rezaie Hospice and Palliative Medicine median Middle half National median
2019 $233 $80 $22–$147 $163
2020 $478 $36 $18–$121 $114
2021 $556 $64 $23–$194 $132
2022 $401 $67 $22–$158 $149
2023 $368 $65 $25–$149 $160
2024 $424 $75 $25–$158 $164
2025 $1,053 $78 $28–$160 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $535 37 payments
  2. Daiichi Sankyo Inc. $364 16 payments
  3. Novo Nordisk Inc $279 14 payments
  4. Allergan Inc. $176 8 payments
  5. Sirtex Medical Inc $146 1 payment
  6. Amgen Inc. $145 9 payments
  7. E.R. Squibb & Sons, L.L.C. $135 1 payment
  8. Salix Pharmaceuticals, a division of Bausch Health US, LLC $131 7 payments
  9. AstraZeneca Pharmaceuticals LP $125 5 payments
  10. Merck Sharp & Dohme Corporation $116 7 payments
  11. Other $1,361 68 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,513 173 payments
Products named General payments · program years 2019–2025
  1. ENHERTU $312 13 payments
  2. UBRELVY Neuroscience $252 17 payments
  3. RYBELSUS $236 11 payments
  4. UBRELVY Neuroscience $176 8 payments
  5. VRAYLAR $164 11 payments
  6. SIR-Spheres Microspheres $146 1 payment
  7. Repatha $145 9 payments
  8. REBLOZYL $135 1 payment
  9. AIMOVIG $133 8 payments
  10. XIFAXAN $131 7 payments
  11. Other $2,580 142 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 84 drugs

Part D claims

4,515

Median for Internal Medicine: 777

Drug cost

$497,662

Median for Internal Medicine: $73,373

Branded share of claims

29.7%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xtampza Er Oxycodone Myristate Brand 135 $119,722
Genvoya Elviteg/Cob/Emtri/Tenof Alafen Brand 23 $91,816
Eliquis Apixaban Brand 42 $38,420
Jardiance Empagliflozin Brand 26 $37,410
Fentanyl Generic 235 $31,902
Oxycontin Oxycodone Hcl Brand 22 $28,598
Movantik Naloxegol Oxalate Brand 47 $21,745
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 486 $19,697
Mounjaro Tirzepatide Brand 11 $19,208
Januvia Sitagliptin Phosphate Brand 11 $14,981

The 10 drugs with the highest cost, of 84 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 55 billing codes

Paid by Medicare

$49,080

Medicare's payments for the services billed

Medicare patients

253

Average age 73

Services billed

679

152 women, 101 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 47%
Cancer 46%
Diabetes 29%
Chronic kidney disease 28%
Depression 28%
Ischemic heart disease 25%
COPD 21%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 15 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ENHERTU
  • Daiichi Sankyo Inc. $132
$132 — —
SARCLISA
  • GENZYME CORPORATION $30
$30 — —
PROLATE
  • Forte Bio-Pharma LLC $30
$30 — —
IMFINZI
  • AstraZeneca Pharmaceuticals LP $28
$28 — —
KEYTRUDA
  • Merck Sharp & Dohme Corporation $24
$24 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 15 in the dashboard with a free account

Records

173 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Hospice and Palliative Medicine in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record